Search

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

Journal: Current Cancer Drug Targets
Volume: 15 Issue: 8 Year: 2015 Page: 665-683
Author(s): Otília Menyhart,Libero Santarpia,Balazs Gyorffy

Journal: Current Cancer Drug Targets
Volume: 11 Issue: 6 Year: 2011 Page: 714-733
Author(s): M. W. Wiedmann, J. Mossner

Patent Selections:

Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 11 Issue: 3 Year: 2016 Page: 352-358
Author(s):

Targeting the EGF/HER Ligand-Receptor System in Cancer

Journal: Current Pharmaceutical Design
Volume: 22 Issue: 39 Year: 2016 Page: 5887-5898
Author(s): Azucena Esparís-Ogando,Juan Carlos Montero,Joaquín Arribas,Alberto Ocaña,Atanasio Pandiella

Heregulin in Breast Cancer: Old Story, New Paradigm

Journal: Current Pharmaceutical Design
Volume: 20 Issue: 3 Year: 2014 Page: 4874-4878
Author(s): Ashwani Khurana, Anatilde Gonzalez-Guerrico, Ruth Lupu

Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity

Journal: Current Cancer Drug Targets
Volume: 19 Issue: 5 Year: 2019 Page: 400-407
Author(s): Jie An,M. Saeed Sheikh

Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance

Journal: Current Medicinal Chemistry
Volume: 19 Issue: 7 Year: 2012 Page: 1065-1075
Author(s): R. Nahta

Strategic Combination Therapies for Ovarian Cancer

Journal: Current Cancer Drug Targets
Volume: 20 Issue: 8 Year: 2020 Page: 573-585
Author(s): Xinran Li,Angel S.N. Ng,Victor C.Y. Mak,Karen K.L. Chan,Annie N.Y. Cheung,Lydia W.T. Cheung

ErbB Antagonists Patenting: “Playing Chess with Cancer”

Journal: Recent Patents on Biotechnology
Volume: 2 Issue: 3 Year: 2008 Page: 181-187
Author(s): Sami Aifa, Ahmed Rebai

Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer

Journal: Current Pharmaceutical Design
Volume: 24 Issue: 11 Year: 2018 Page: 1195-1203
Author(s): Atefeh Arab,Rezvan Yazdian Robati,Jessica Nicastro,Roderick Slavcev,Javad Behravan